• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    VivoSim Labs Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    12/18/25 4:05:25 PM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VIVS alert in real time by email
    8-K
    0001497253false00014972532025-12-162025-12-16

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): December 16, 2025

     

     

    VivoSim Labs, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-35996

    27-1488943

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    11555 Sorrento Valley Rd

    Suite 100

     

    San Diego, California

     

    92121

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (858) 224-1000

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.001 par value

     

    VIVS

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 5.07 Submission of Matters to a Vote of Security Holders.

    On December 16, 2025, VivoSim Labs, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 2,607,962 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issued and outstanding as of the October 17, 2025 record date, 972,769 shares, or 37.29%, constituting a quorum, were represented at the Annual Meeting either virtually or by proxy.

    A description of each proposal voted upon at the Annual Meeting is described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 3, 2025 (the “Proxy Statement”).Set forth below is a brief description of each proposal voted upon at the Annual Meeting and the voting results with respect to each proposal.

    (1) Election of Directors. The Company’s stockholders elected Douglas Jay Cohen and David Gobel as Class II directors, each to hold office until the 2028 Annual Meeting of Stockholders and until his respective successor is elected and qualified. The following table shows the tabulation of the votes cast “For” and “Withheld” for each of Mr. Cohen and Mr. Gobel as well as the “Broker Non-Votes” submitted for this proposal:

     

    Director

     

    For

     

    Withheld

     

    Broker Non-Votes

    Douglas Jay Cohen

     

    212,079

     

    15,531

     

    745,159

     

    Director

     

    For

     

    Withheld

     

    Broker Non-Votes

    David Gobel

     

    212,420

     

    15,190

     

    745,159

     

    (2) Ratification of Auditors. The Company’s stockholders ratified the appointment of Rosenberg Rich Baker Berman P.A. as the Company’s independent registered public accounting firm for the fiscal year ending March 31, 2026, with the approval of 97.91% of the votes cast. The following table shows the tabulation of the votes cast “For” and “Against” this proposal as well as the “Abstentions” submitted for this proposal:

     

    For

     

    Against

     

    Abstentions

    935,525

     

    19,923

     

    17,321

    (3) Advisory Vote on the Compensation of Named Executive Officers. The Company’s stockholders, on a non-binding, advisory basis, approved the compensation of the Company’s named executive officers as disclosed in the Proxy Statement, with the approval of 89.97% of the votes cast. The following table shows the tabulation of the votes cast “For” and “Against” this proposal as well as the “Abstentions” and “Broker Non-Votes” submitted for this proposal:

     

    For

     

    Against

     

    Abstentions

     

    Broker Non-Votes

    193,240

     

    21,542

     

    12,828

     

    745,159

     

    (4) Frequency of Advisory Vote on Executive Compensation. The Company’s stockholders approved the frequency, on a non-binding, advisory basis, of “one year” on the frequency of future stockholder votes on executive compensation, with 97.17% of the votes cast for “one year”. The following table shows the tabulation of the votes cast for “one year”, “two years” and “three years”, as well as the “Abstentions” submitted for this proposal:
     

    One Year

     

    Two Years

     

    Three Years

     

    Abstentions

    207,095

     

    974

     

    5,053

     

    14,488

     

    In light of the advisory vote of the Company’s stockholders to hold future advisory votes on the compensation of the Company’s named executive officers every one year, the Company has determined that it will hold future advisory votes on the compensation of the Company’s named executive officers on an annual basis until the next stockholder advisory vote on the frequency of future advisory votes on the compensation of the Company’s named executive officers.

    No other items were presented for stockholder approval at the Annual Meeting.


    Item 9.01 Financial Statements and Exhibits.

     

    Exhibit

    No.

     

    Description

     

     

     

     

     

    104

     

    Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

     

    VivoSim Labs, Inc.

     

     

     

     

    Date:

    December 18, 2025

    By:

    /s/ Keith Murphy

     

     

     

    Name: Keith Murphy
    Title: Executive Chairman

     


    Get the next $VIVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VIVS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VIVS
    SEC Filings

    View All

    VivoSim Labs Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - VivoSim Labs, INC. (0001497253) (Filer)

    12/18/25 4:05:25 PM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by VivoSim Labs Inc.

    10-Q - VivoSim Labs, INC. (0001497253) (Filer)

    11/6/25 4:08:13 PM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by VivoSim Labs Inc.

    DEFA14A - VivoSim Labs, INC. (0001497253) (Filer)

    11/3/25 4:07:49 PM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

    SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ("3D") human tissue models of liver and intestine, announced today that it has appointed Tony Lialin as its Chief Commercial Officer. Mr. Lialin brings more than two decades of experience turning breakthrough life science platforms into scalable, predictable revenue. He has built commercial teams from the ground up, forged strategic pharma partnerships, and helped scale multiple businesses that were later acquired by leading industry players

    8/14/25 8:05:12 AM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    VivoSim's NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference

    SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim") announced today that its NAMkind™ platform for intestinal efficacy prediction was recognized with a blue ribbon "Poster of Distinction" award at the Digestive Disease Week Conference (San Diego, CA, May 2-6, 2025). The work describes developing a robust, multicellular in vitro model that closely mirrors human intestinal biology, paving the way for safer and more effective therapies for inflammatory bowel disease (IBD). The Company's award-winning research showcased a physiologically relevant system built from primary human cells derived from both healthy donors and patients with Ulcer

    5/13/25 8:05:27 AM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Scientific Officer Sethi Amar Akhtar

    4 - VivoSim Labs, INC. (0001497253) (Issuer)

    11/26/25 6:09:37 PM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Sethi Amar Akhtar

    3 - VivoSim Labs, INC. (0001497253) (Issuer)

    11/26/25 6:07:57 PM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Gobel David

    4 - VivoSim Labs, INC. (0001497253) (Issuer)

    11/19/25 4:01:04 PM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIVS
    Leadership Updates

    Live Leadership Updates

    View All

    VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

    SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ("3D") human tissue models of liver and intestine, announced today that it has appointed Tony Lialin as its Chief Commercial Officer. Mr. Lialin brings more than two decades of experience turning breakthrough life science platforms into scalable, predictable revenue. He has built commercial teams from the ground up, forged strategic pharma partnerships, and helped scale multiple businesses that were later acquired by leading industry players

    8/14/25 8:05:12 AM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care